- Home
- EML vs STTK Comparison
EML vs STTK Comparison
Compare EML & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- STTK
- Stock Information
- Founded
- EML 1858
- STTK 2016
- Country
- EML United States
- STTK United States
- Employees
- EML N/A
- STTK N/A
- Industry
- EML Industrial Machinery/Components
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- STTK Health Care
- Exchange
- EML Nasdaq
- STTK Nasdaq
- Market Cap
- EML 171.1M
- STTK 173.6M
- IPO Year
- EML N/A
- STTK 2020
- Fundamental
- Price
- EML $29.87
- STTK $3.64
- Analyst Decision
- EML
- STTK Strong Buy
- Analyst Count
- EML 0
- STTK 3
- Target Price
- EML N/A
- STTK $10.67
- AVG Volume (30 Days)
- EML 36.0K
- STTK 152.9K
- Earning Date
- EML 08-06-2024
- STTK 11-07-2024
- Dividend Yield
- EML 1.47%
- STTK N/A
- EPS Growth
- EML 65.47
- STTK N/A
- EPS
- EML 1.92
- STTK N/A
- Revenue
- EML $273,702,675.00
- STTK $4,123,999.00
- Revenue This Year
- EML N/A
- STTK $164.45
- Revenue Next Year
- EML N/A
- STTK N/A
- P/E Ratio
- EML $15.51
- STTK N/A
- Revenue Growth
- EML N/A
- STTK 380.09
- 52 Week Low
- EML $16.10
- STTK $1.33
- 52 Week High
- EML $35.78
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- EML 54.35
- STTK 51.46
- Support Level
- EML $29.30
- STTK $3.37
- Resistance Level
- EML $31.35
- STTK $3.75
- Average True Range (ATR)
- EML 1.00
- STTK 0.23
- MACD
- EML -0.06
- STTK 0.07
- Stochastic Oscillator
- EML 47.67
- STTK 78.85
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.